The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1115
October 15, 2001
View Complete Issue         Table of Contents 2019 
Insulin Aspart, A New Rapid-acting Insulin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Insulin Aspart, A New Rapid-acting Insulin
October 15, 2001 (Issue: 1115)
Insulin aspart (Novolog - Novo Nordisk) is the second rapid-acting insulin analog to be approved by the FDA. The first was insulin lispro (Humalog). Insulin aspart differs from human insulin by substitution of aspartic acid for proline in position 28...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Aspart, A New Rapid-acting Insulin
Article code: 1115b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.